For pediatric patients with inflammatory bowel disease (IBD), treating iron deficiency anemia (IDA) with intravenous iron sucrose is both safe and possibly effective, according to findings from a recent retrospective chart review.
The chart review included 72 pediatric IBD patients who received infusions of iron sucrose for the treatment of IDA between 2011 and 2015 at a single tertiary care center. Of the 72 patients included, 53 had Crohn’s disease, 11 had ulcerative colitis, and 8 had an unclassified type of IBD, and a total of 43 patients qualified for and were included in the efficacy analysis.
The study authors reported, “There was a significant increase in hemoglobin over the treatment course, with mean (±SD) hemoglobin increasing from 9.6 ± 1.2 g/dL at baseline to 12.1 ± 1.3 g/dL after iron sucrose treatment (P<0.001).” Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions), however, none of these adverse events required hospitalization, were life-threatening, or were considered anaphylactic in nature.
Based on this chart review, iron sucrose administered intravenously is a safe and possibly effective option for the treatment of IDA in pediatric patients with IBD.
For more information visit Ovid.com.